Ken Garber

Ken Garber's AcademicInfluence.com Rankings

Ken Garber

Biology

#11745

World Rank

#15167

Historical Rank

biology Degrees

Download Badge

Biology

Ken Garber's Degrees

Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Ken Garber Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ken Garber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

China approves world's first oncolytic virus therapy for cancer treatment. (2006) (460)
Energy Deregulation: Licensing Tumors to Grow (2006) (272)
Energy boost: the Warburg effect returns in a new theory of cancer. (2004) (209)
RIKEN suspends first clinical trial involving induced pluripotent stem cells (2015) (191)
From human to mouse and back: 'tumorgraft' models surge in popularity. (2009) (140)
Autism's Cause May Reside in Abnormalities at the Synapse (2007) (112)
Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. (2008) (112)
Driving T-cell immunotherapy to solid tumors (2018) (109)
Bispecific antibodies rise again (2014) (103)
Alnylam launches era of RNAi drugs (2018) (102)
HDAC inhibitors overcome first hurdle (2007) (97)
Rapamycin's resurrection: a new way to target the cancer cell cycle. (2001) (87)
Stromal depletion goes on trial in pancreatic cancer. (2010) (69)
Drugging the Wnt pathway: problems and progress. (2009) (66)
The second wave in kinase cancer drugs (2006) (63)
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis (2011) (60)
Gene Expression Tests Foretell Breast Cancer's Future (2004) (59)
Notch emerges as new cancer drug target. (2007) (56)
Angiogenesis inhibitors suffer new setback (2002) (56)
Improved Paclitaxel formulation hints at new chemotherapy approach. (2004) (55)
A new cancer immunotherapy suffers a setback. (2018) (54)
First results for agents targeting cancer-related inflammation. (2009) (53)
No longer going to waste (2016) (52)
Drugging the gut microbiome (2015) (50)
Peptide leads new class of chronic pain drugs (2005) (48)
The PROTAC gold rush (2021) (48)
Anti-IL-17 mAbs herald new options in psoriasis (2012) (47)
Genentech's Alzheimer's antibody trial to study disease prevention (2012) (47)
MET inhibitors start on road to recovery (2014) (45)
IGF-1: old growth factor shines as new drug target. (2005) (44)
New apoptosis drugs face critical test (2005) (43)
BIOMEDICINE. Targeting copper to treat breast cancer. (2015) (43)
Realistic rodents? Debate grows over new mouse models of cancer. (2006) (43)
Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia. (2010) (40)
Biotech industry faces new bottleneck (2001) (39)
Alnylam terminates revusiran program, stock plunges (2016) (37)
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market (2013) (37)
Cancer anabolic metabolism inhibitors move into clinic (2016) (35)
PARP inhibitors bounce back (2013) (35)
Debate rages over proteomic patterns. (2004) (34)
ALK, lung cancer, and personalized therapy: portent of the future? (2010) (33)
Cancer research. Melanoma drug vindicates targeted approach. (2009) (33)
Fixing the front end (2008) (33)
Inducing indigestion: companies embrace autophagy inhibitors. (2011) (32)
Promising early results for immunotherapy-antiangiogenesis combination. (2014) (32)
Stroke treatment—light at the end of the tunnel? (2007) (31)
Companies waver in efforts to target transforming growth factor beta in cancer. (2009) (31)
Parkinson's disease and cancer: the unexplored connection. (2010) (29)
Beyond ipilimumab: new approaches target the immunological synapse. (2011) (29)
Fate of novel painkiller mAbs hangs in balance (2011) (29)
New checkpoint blockers begin human trials. (2005) (28)
Hedgehog drugs begin to show results. (2008) (28)
Missing the target: ubiquitin ligase drugs stall. (2005) (28)
Targeting mTOR: something old, something new. (2009) (28)
The Elusive ALS Genes (2008) (28)
Biochemistry: A radical treatment (2012) (26)
Hepatitis C: move over interferon (2011) (26)
Autophagy. Explaining exercise. (2012) (25)
Inducing translation (2013) (25)
Immunology: A tolerant approach (2014) (24)
Psoriasis: from bed to bench and back (2011) (24)
Taking Garbage In, Tossing Cancer Out? (2002) (24)
Patently absurd? (2006) (24)
The cancer drug that almost wasn't. (2014) (24)
New drugs target hypoxia response in tumors. (2005) (23)
Personal mouse colonies give hope for pancreatic cancer patients. (2007) (23)
A β-lactamase inhibitor revival provides new hope for old antibiotics (2015) (23)
Immune agonist antibodies face critical test (2019) (22)
Of Ephs and ephrins: companies target guidance molecules in cancer. (2010) (22)
Worth the RISC? (2017) (22)
Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up (2019) (22)
Cancer's copper connections. (2015) (21)
Tissue-agnostic cancer drug pipeline grows, despite doubts (2018) (20)
First microbiome-based drug clears phase III, in clinical trial turnaround (2020) (20)
Aspirin for cancer chemoprevention: still a headache? (2004) (20)
A mid-life crisis for aging theory (2008) (19)
Targeting mitochondria emerges as therapeutic strategy. (2005) (19)
In a major shift, cancer drugs go 'tissue-agnostic'. (2017) (19)
Lymphoma rate rise continues to baffle researchers. (2001) (19)
Big win possible for Ionis/Biogen antisense drug in muscular atrophy (2016) (18)
Kinase inhibitors overachieve in CLL (2014) (18)
Purchase of Aton spotlights HDAC inhibitors (2004) (18)
Genetics: Deep exploration (2012) (18)
Synthetic lethality: killing cancer with cancer. (2002) (18)
Two pioneering osteoporosis drugs finally approach approval (2016) (17)
Cancer stem cell pipeline flounders (2018) (17)
Divide and conquer: new generation of drugs targets mitosis. (2005) (17)
γδ T cells bring unconventional cancer-targeting to the clinic — again (2020) (17)
Oncology's energetic pipeline (2010) (17)
rFactor VIII deficit questioned (2000) (16)
Breaking the silence: the rise of epigenetic therapy. (2002) (16)
Trial offers early test case for personalized medicine. (2009) (16)
Protein C may be sepsis solution (2000) (15)
Rapamycin may prevent post-transplant lymphoma. (2001) (15)
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy (2017) (15)
Momentum building for human epigenome project. (2006) (15)
Tamoxifen pharmacogenetics moves closer to reality. (2005) (15)
First FDA-approved beta-amyloid diagnostic hits the market (2012) (14)
Predictive biomarkers for checkpoints, first tests approved (2015) (14)
Why it hurts: researchers seek mechanisms of cancer pain. (2003) (14)
Tyrosine kinase inhibitor research presses on despite halted clinical trial. (2000) (13)
Hepatitis C: staying the course (2007) (13)
Cancer research. Taking garbage in, tossing cancer out? (2002) (13)
Human Cancer Genome Project moving forward despite some doubts in community. (2005) (13)
Alnylam's RNAi therapy targets amyloid disease (2015) (12)
Biotech in a blink (2010) (12)
Coronavirus vaccine developers wary of errant antibodies (2020) (11)
A tale of two cells: discovering the origin of prostate cancer. (2010) (11)
New insights into oncogene addiction found. (2007) (11)
Infections cast cloud over Novartis' MS therapy (2008) (11)
Users fear that lymphoma drugs will disappear. (2007) (11)
Ready or not: personal tumor profiling tests take off. (2011) (11)
Biologics inch toward cholesterol-lowering market (2012) (11)
Beyond the Nobel Prize: cell cycle research offers new view of cancer. (2001) (10)
Researchers target unfolded protein response in cancerous tumor growth. (2006) (10)
Melanoma combination therapies ward off tumor resistance (2013) (10)
At the frontiers of lung fibrosis therapy (2013) (10)
Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses (2018) (10)
Could less be more? Low-dose chemotherapy goes on trial. (2002) (10)
The new liver epidemic (2019) (10)
JAK2 inhibitors: not the next imatinib but researchers see other possibilities. (2009) (10)
Industry 'road tests' new wave of immune checkpoints (2017) (10)
Targeting vessel abnormalization in cancer. (2007) (9)
Make or break for costimulatory blockers (2004) (9)
Industry makes strides in melanoma (2010) (9)
Small RNAs Reveal an Activating Side (2006) (8)
Blood test may predict cancer immunotherapy benefit. (2018) (8)
Nature Biotechnology’s academic spinouts of 2018 (2019) (7)
Immunology's quiet upheaval (2009) (7)
Natural killer cells blaze into immuno-oncology (2016) (7)
No miR hype: microRNA's cancer role expands. (2006) (7)
Epigenetics comes to RNA. (2019) (7)
Genetics. Small RNAs reveal an activating side. (2006) (7)
Big plans for small molecules: NIH launches chemical genomics initiative. (2003) (7)
CELL BIOLOGY. Protein 'drops' may seed brain disease. (2015) (7)
Silence of the genes: cancer epigenetics arrives. (2002) (6)
At loose ends: telomere theories of aging and cancer begin to converge. (2012) (6)
No added sugar: antibody makers find an upside to 'no fucose' (2018) (6)
Adenosine checkpoint agent blazes a trail, joins immunotherapy roster (2017) (6)
RAC Urges Changes to Retinoblastoma Plan (1999) (6)
New gene discoveries may boost DNA stool testing for colorectal cancer. (2004) (6)
Translational Institute Unites Unlikely Partners at Penn (2007) (6)
New discoveries still abundant in monoclonal antibody research. (2000) (5)
ODAC panel gives nod to Bexxar. (2003) (5)
Controversial allocation rules for liver transplants (2002) (5)
Histone-writer cancer drugs enter center stage (2020) (5)
Ontario institute offers new model of cancer research. (2008) (5)
Beyond sequencing: new diagnostic tests turn to pathways. (2011) (5)
Evading immunity: new enzyme implicated in cancer. (2012) (5)
Trial results boost circulating tumor cell field. (2004) (5)
Hunt for improved monoclonals against coronavirus gathers pace (2021) (5)
STI571 revolution: can the newer targeted drugs measure up? (2001) (5)
Between disease and a dish (2014) (5)
For Bexxar, FDA meeting offers long-awaited chance at approval. (2002) (4)
Sugen falls as casualty of Pfizer–Pharmacia merger (2003) (4)
Broad Patent Faces Narrow Odds in Court Battle (2006) (4)
Erratum: Near-optimal probabilistic RNA-seq quantification (2016) (4)
The clot stopper. (2006) (4)
Better blocker: RNA interference dazzles research community. (2003) (4)
Battle over generic taxol concludes, but controversy continues. (2002) (4)
Running interference: pace picks up on synthetic lethality research. (2004) (4)
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure. (2003) (4)
A promising new cancer drug has hit a major setback, raising questions about whether the field is moving too fast (2018) (4)
First metabolic oncology inhibitor gets FDA green light, with record price tag (2017) (4)
Principia Biopharma (2013) (3)
Decision on NFκB Patent Could Have Broad Implications for Biotech (2006) (3)
Year of the Cat--in More Ways Than One (1998) (3)
Lymphoma market turf war imminent, pending Bexxar approval (2003) (3)
First-in-class biologic to enter rheumatoid arthritis fray (2005) (3)
Newsmaker: Lycera (2011) (3)
The next wave of the genomics business (2000) (3)
Neurodegeneration. Potential Alzheimer's drug spurs protein recycling. (2014) (3)
Troubled big pharma turns away from biotech (2002) (3)
Genetic discoveries propagate new epigenetic drugs. (2012) (3)
RAC nixes plan to treat retinoblastoma. (1999) (3)
Melanoma antibody approved (2011) (3)
On the eve of protein destruction: ubiquitin research begins to pay off. (2002) (2)
Erratum: The long view on sequencing (2018) (2)
US NHGRI launches chemical attack on drug development gap (2003) (2)
Companies Waver in Efforts To Target Transforming Growth Factor (cid:1) in Cancer (2009) (2)
Science careers. Translational institute unites unlikely partners at Penn. (2007) (2)
Gene mutation revelation points to new target for myeloma treatment, studies say. (2007) (2)
Amyloid disease drug approved (2012) (2)
Nature Biotechnology’s academic spinouts 2021 (2022) (1)
mRNA pioneers refocus on therapeutics (2022) (1)
Oncologists push beyond new lung cancer genomic testing guidelines. (2015) (1)
New method found to trigger cancer cell suicide. (2006) (1)
Orna Therapeutics: circular logic. (2022) (1)
Nature Biotechnology's academic spinouts of 2017 (2018) (1)
Erratum: No longer going to waste (2016) (1)
Erratum: Fate of novel painkiller mAbs hangs in balance (2012) (1)
Bristol-Myers Squibb locks into novel autoimmune strategy (2016) (1)
Ariad's NFκB patent claims shot down on appeal (2009) (1)
Proteostasis Therapeutics (2009) (1)
Publisher Correction: γδ T cells bring unconventional cancer-targeting to the clinic — again (2020) (1)
Synthekine: beyond cytokines. (2021) (1)
Neuroscience. All eyes on RNA. (2012) (1)
Varietal trials with flax in Schleswig-Holstein with special reference to quality. (1960) (1)
Mutation-counting blood test could predict if cutting-edge immunotherapies can beat a cancer (2018) (1)
The new liver epidemic (2019) (0)
“Troubled big pharma turns away from biotech” (2002) (0)
Delix Therapeutics : psychedelics without the trip. (2022) (0)
Tech transfer pays off (2002) (0)
Publisher Correction: γδ T cells bring unconventional cancer-targeting to the clinic — again (2020) (0)
NIH licensing performance under par. (2004) (0)
Ariad's NF-κB blow (2010) (0)
Mission Therapeutics (2012) (0)
Correction: Corrigendum: Editors' Pick: Orphazyme (2013) (0)
Erratum: Nature Biotechnology's academic spinouts of 2017 (2018) (0)
Van Andel Institute brings cancer research to the heartland. (2001) (0)
Erratum: Drugging the gut microbiome (2017) (0)
Immune agonist antibodies face critical test (2019) (0)
Erratum: Make or break for costimulatory blockers (2004) (0)
First Rounders: Nina Tandon (2019) (0)
Hunt for improved monoclonals against coronavirus gathers pace (2021) (0)
Hidden layer of gene control influences everything from cancer to memory (2019) (0)
The lysosomal degraders. (2022) (0)
Publisher Correction: Histone-writer cancer drugs enter center stage (2020) (0)
Erratum: Make or break for costimulatory blockers (2004) (0)
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy (2017) (0)
Tumor macrophage target fuels $1.7-billion deal (2015) (0)
Erratum: Biotech in a blink (2010) (0)
Nature Biotechnology’s academic spinouts 2020 (2021) (0)